However, multiple intercellular cross-talk of MSCs with myeloma cells or other cells in the BMmilieu (through cell contact, soluble factors, or extracellular vesicles) deregulate the commented pathways or finally affect Runx2 activity, greatly influencing the osteogenic capacity of MSCs. The gene discussed is RUNX2; the disease is plasma cell myeloma.